Zacks Investment Research Lowers Arbutus Biopharma (NASDAQ:ABUS) to Sell

Zacks Investment Research cut shares of Arbutus Biopharma (NASDAQ:ABUS) from a hold rating to a sell rating in a report published on Tuesday, Zacks.com reports.

According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. “

Several other analysts have also commented on the company. Echelon Wealth Partners reaffirmed a hold rating on shares of Arbutus Biopharma in a research note on Monday, March 11th. ValuEngine lowered Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $6.25.

Shares of ABUS stock opened at $2.35 on Tuesday. The company has a fifty day moving average of $1.96. The company has a current ratio of 12.75, a quick ratio of 12.75 and a debt-to-equity ratio of 0.06. The firm has a market cap of $130.76 million, a price-to-earnings ratio of -2.30 and a beta of 1.87. Arbutus Biopharma has a one year low of $1.42 and a one year high of $12.60.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.16). The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.18 million. Arbutus Biopharma had a negative net margin of 1,237.92% and a negative return on equity of 95.26%. As a group, research analysts anticipate that Arbutus Biopharma will post -1.56 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of ABUS. DekaBank Deutsche Girozentrale increased its holdings in shares of Arbutus Biopharma by 21.1% in the first quarter. DekaBank Deutsche Girozentrale now owns 34,500 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 6,000 shares during the period. Alps Advisors Inc. increased its holdings in shares of Arbutus Biopharma by 4.7% in the first quarter. Alps Advisors Inc. now owns 134,053 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 6,016 shares during the period. SG Americas Securities LLC increased its holdings in shares of Arbutus Biopharma by 18.8% in the first quarter. SG Americas Securities LLC now owns 57,454 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 9,078 shares during the period. Bank of Montreal Can increased its holdings in shares of Arbutus Biopharma by 1.2% in the first quarter. Bank of Montreal Can now owns 979,124 shares of the biopharmaceutical company’s stock worth $3,505,000 after purchasing an additional 11,520 shares during the period. Finally, BNP Paribas Arbitrage SA bought a new position in shares of Arbutus Biopharma in the first quarter worth $26,000. Hedge funds and other institutional investors own 41.76% of the company’s stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Featured Story: Why do analysts give a neutral rating?

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.